Post-Operative Pain - Pipeline Review, H1 2014

  • Share on Google+

Global Markets Direct

2014 Jun 30

157 Pages (PDF)




Post-Operative Pain - Pipeline Review, H1 2014

Summary

Global Markets Directs, Post-Operative Pain - Pipeline Review, H1 2014, provides an overview of the Post-Operative Pains therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Post-Operative Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Post-Operative Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post-Operative Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Post-Operative Pain Overview 10
Therapeutics Development 11
Pipeline Products for Post-Operative Pain - Overview 11
Pipeline Products for Post-Operative Pain - Comparative Analysis 12
Post-Operative Pain - Therapeutics under Development by Companies 13
Post-Operative Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Post-Operative Pain - Products under Development by Companies 19
Post-Operative Pain - Companies Involved in Therapeutics Development 21
DURECT Corporation 21
Boehringer Ingelheim GmbH 22
Hospira, Inc. 23
Medtronic, Inc. 24
Terumo Corporation 25
UMeWorld Limited 26
Takeda Pharmaceutical Company Limited 27
Heron Therapeutics, Inc. 28
AcelRx Pharmaceuticals, Inc. 29
Laboratorios Del Dr. Esteve S.A. 30
Orion Corporation 31
Pfizer Inc. 32
A. Menarini Industrie Farmaceutiche Riunite Srl 33
Luitpold Pharmaceuticals, Inc. 34
GW Pharmaceuticals plc 35
AngioChem Inc. 36
Galleon Pharmaceuticals 37
Trevena, Inc. 38
Omeros Corporation 39
Cara Therapeutics, Inc. 40
Encore Therapeutics Inc. 41
Flexion Therapeutics, Inc. 42
Ocular Therapeutix, Inc. 43
Adynxx, Inc. 44
Echo Pharmaceuticals B.V. 45
Recro Pharma, Inc. 46
Post-Operative Pain - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 53
Assessment by Route of Administration 57
Assessment by Molecule Type 60
Drug Profiles 62
ARX-01 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
(ketorolac tromethamine + phenylephrine ) - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
diclofenac sodium - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
bupivacaine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ketorolac tromethamine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
(ketoprofen + amitriptyline + oxymetazoline) - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
acetaminophen - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
dexamethasone acetate SR - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
nabiximols - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CR-4056 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
TRV-130 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CR-845 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
dexmedetomidine hydrochloride - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
RNS-60 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
PF-05089771 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
dronabinol - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
ropivacaine ER - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
E-52862 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
AYX-1 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
fadolmidine hydrochloride - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
AM-4 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
MDT-10013 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
BI-1026706 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
CMX-020 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
VVZ-149 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
ANG-2002 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
ARX-8203 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
FX-007 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
ropivacaine ER - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
buprenorphine hydrochloride ER - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
grapiprant - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
GIBH-1014 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
bupivacaine - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
ropivacaine - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
ARX-8028 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
GAL-044 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Post-Operative Pain - Recent Pipeline Updates 116
Post-Operative Pain - Dormant Projects 147
Post-Operative Pain - Discontinued Products 148
Post-Operative Pain - Product Development Milestones 149
Featured News & Press Releases 149
May 07, 2014: Pacira Pharmaceuticals Announces sNDA Submission for EXPAREL Nerve Block Indication 149
May 02, 2014: Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting 149
May 01, 2014: Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain 150
Apr 07, 2014: Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity 151
Apr 04, 2014: EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014 151
Mar 31, 2014: Pacira Pharmaceuticals Announces FDA Approval of Additional Manufacturing Suite for EXPAREL 152
Mar 17, 2014: Antibe Therapeutics Announces Completion of Pre-Clinical Program for ATB-346 152
Mar 17, 2014: Ocular Therapeutix Begins Phase 3 Clinical Trial for its Sustained Release Dexamethasone 153
Mar 14, 2014: Two New Studies Support Use of EXPAREL for Postsurgical Pain Management Following Total Joint Replacement 153
Mar 12, 2014: Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent 154
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 157
Disclaimer 157
DURECT Corporation
Boehringer Ingelheim GmbH
Hospira, Inc.
Medtronic, Inc.
Terumo Corporation
UMeWorld Limited
Takeda Pharmaceutical Company Limited
Heron Therapeutics, Inc.
AcelRx Pharmaceuticals, Inc.
Laboratorios Del Dr. Esteve S.A.
Orion Corporation
Pfizer Inc.
A. Menarini Industrie Farmaceutiche Riunite Srl
Luitpold Pharmaceuticals, Inc.
GW Pharmaceuticals plc
AngioChem Inc.
Galleon Pharmaceuticals
Trevena, Inc.
Omeros Corporation
Cara Therapeutics, Inc.
Encore Therapeutics Inc.
Flexion Therapeutics, Inc.
Ocular Therapeutix, Inc.
Adynxx, Inc.
Echo Pharmaceuticals B.V.
Recro Pharma, Inc.				
Full Name
Email
Job Title
Mobile
Your Requirement
Full Name
Email
Job Title
Mobile
Your Requirement